Considerations for choosing an appropriate factor product
More frequent dosing may provide higher factor levels1
Depending on patients' needs and lifestyles, continuing with or switching to an SHL factor product may represent an appropriate option.1
Higher factor levels and more frequent peaks may be needed for some patients.1
Patient profiles are hypothetical and for discussion purposes only.
Lorem ipsum dolor sit amet, consectetur badipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Who is Aamir?
Stable on BeneFIX®
A 42 year-old male patient with moderate hemophilia B. He is a local community leader who started a hiking club for his neighbourhood.
Treatment
Aamir has not experienced any bleeding episodes in the past year. He has been on prophylaxis with BeneFIX® for 20 years and likes the predictable routine and coverage it provides.
Patients currently on SHL factor therapy may wish to consider remaining on SHL therapy if higher levels and more frequent peaks are more appropriate for them.1 Dose and duration of the substitution therapy depend on the severity of the FIX deficiency, the location and extent of bleeding, and the patient's clinical condition.4
Why BeneFIX® may be appropriate for patients like Aamir
![]() for prophylaxis, on-demand and surgery5,7,8 |
|||
![]() storage flexibility through room temperature storage (2 - 30 °C).4 Do not freeze4 |
|||
![]() with a predictable PK to support your patient's everyday life10 |
|||
![]() with low inhibitor formation6 |
|||
![]() (250, 500, 1000, 2000, 3000 IU) so you can individualise FIX coverage for your patients4 |
Informed decisions may lead to more favourable outcomes.1,3
To help ensure that patients are actively involved in creating their treatment plan, consider discussing the following points to help determine if an SHL or an EHL is more appropriate:
*A target joint is a joint in which 3 or more spontaneous bleeds occurred within a consecutive 6-month period.9
EHL, extended half-life; FIX, factor IX; PK, pharmacokinetics; SHL, standard half-life.
References:
PP-BEN-IND-0025 22/07/22
BeneFIX® provides dosing options based on individual needs
Learn more
Proven efficacy and protection across dosing regimen
Review efficacy profile
See how BeneFIX® performs in real-life settings.
Review real-world data
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.